By pharmacological intervention with IL-1βR antagonist or NLRP3 inhibitor, cardiac arrhythmias were ameliorated, which indicated that activation of NLRP3 inflammasome was implicated in diabetic cardiomyopathy [91]. Here, NLRP3 is linked to cardiac rhythm disease.